Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

NCT01976208 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

630

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: Omalizumab
DRUG: placebo

Sponsor

Shanghai Zhangjiang Biotechnology Limited Company